In brief, we showed for the first time that TG101209, a specific JAK2 inhibitor, could inhibit Burkitt lymphoma growth, induce cycle arrest, differentiation and apoptosis of BL cells, and prolong the survival of Ramos cell-bearing mice by inhibiting the JAK2/STAT3/c-MYB signaling axis. This evidence concerns the gene JAK2 and Burkitt lymphoma.